Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03076515 · ClinicalTrials.gov registry record · NA
Migraine Treatment With Nerivio Migra Neurostimulation Device
A NA study, sponsored by Theranica.
- Terminated
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT03076515 is a NA study that was terminated before completion, run by Theranica. The registered enrollment target is 120 participants.
The verdict
NCT03076515, a NA study, was terminated before completion, sponsored by Theranica.
- TERMINATED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.
Interventions
- DEVICE Nerivio Migra neurostimulation
- DEVICE Sham Nerivio Migra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-04-02 |
| Est. Completion | 2018-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03076515
The ClinicalTrials.gov registry entry for NCT03076515 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nerivio Migra neurostimulation is the first listed.
NCT03076515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03076515 about?
NCT03076515 is a clinical study titled "Migraine Treatment With Nerivio Migra Neurostimulation Device". This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.
What is the current status of trial NCT03076515?
This trial is currently terminated. It is a NA study. The enrollment target is 120 participants. The study started on 2017-04-02. Estimated completion is 2018-04-01.
What interventions are being tested in trial NCT03076515?
The interventions under investigation include: Nerivio Migra neurostimulation (DEVICE), Sham Nerivio Migra (DEVICE).
Who is sponsoring clinical trial NCT03076515?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.